Literature DB >> 208636

Characterization of the oligosaccharide side chain of apolipoprotein C-III from human plasma very low density lipoproteins.

P Vaith, G Assmann, G Uhlenbruck.   

Abstract

Apolipoprotein C-III1 and apolipoprotein C-III2 each contain one oligosaccharide side chain, bound O-glycosidically to threonine in position 74 of the amino acid sequence. The studies reported in this paper characterize these alkali labile oligosaccharides, thereby demonstrating the complete structure of apolipoprotein C-III. Monosaccharide analysis revealed the following sugar composition: D-galactose/N-acetyl-D-galactosamine/sialic acid 1 : 1 : 1 and 1 : 1 : 2 for apolipoprotein C-III1 and apolipoprotein C-III2, respectively. Treatment of desialylated apolipoproteins with alkaline borohydride released the reduced disaccharide beta-D-galactosyl-(1 leads to 3)-N-acetyl-D-galactosaminitol, which was detected by gas-liquid chromatography. Further studies employing periodate oxidation and Smith degradation indicated that the structure of the trisaccharide from apolipoprotein C-III1 was alpha-N-acetylneuraminyl-(2 leads to 3)-beta-D-galactosyl-(1 leads to 3)-N-acetyl-D-galactosaminitol. The tetrasaccharide structure from apolipoprotein C-III2 is made up of this trisaccharide plus one sialic acid residue linked to C6 of N-acetyl-D-galactosaminitol, as was shown by the assessment of chromogens formed upon alkaline degradation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 208636     DOI: 10.1016/0304-4165(78)90396-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

Review 1.  Genetic causes of high and low serum HDL-cholesterol.

Authors:  Daphna Weissglas-Volkov; Päivi Pajukanta
Journal:  J Lipid Res       Date:  2010-04-26       Impact factor: 5.922

2.  Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Authors:  Nathan L Meyers; Mikael Larsson; Evelina Vorrsjö; Gunilla Olivecrona; Donald M Small
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

3.  Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man.

Authors:  Adriaan G Holleboom; Helen Karlsson; Ruei-Shiuan Lin; Thomas M Beres; Jeroen A Sierts; Daniel S Herman; Erik S G Stroes; Johannes M Aerts; John J P Kastelein; Mohammad M Motazacker; Geesje M Dallinga-Thie; Johannes H M Levels; Aeilko H Zwinderman; Jonathan G Seidman; Christine E Seidman; Stefan Ljunggren; Dirk J Lefeber; Eva Morava; Ron A Wevers; Timothy A Fritz; Lawrence A Tabak; Mats Lindahl; G Kees Hovingh; Jan Albert Kuivenhoven
Journal:  Cell Metab       Date:  2011-12-07       Impact factor: 27.287

4.  Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.

Authors:  A von Eckardstein; H Holz; M Sandkamp; W Weng; H Funke; G Assmann
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.

Authors:  Haizhao Yan; Manabu Niimi; Fumikazu Matsuhisa; Huanjin Zhou; Shuji Kitajima; Yajie Chen; Chuan Wang; Xiawen Yang; Jian Yao; Dongshan Yang; Jifeng Zhang; Masami Murakami; Katsuyuki Nakajima; Yao Wang; Enqi Liu; Jingyan Liang; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-08-06       Impact factor: 8.311

6.  Lipoprotein secretion by isolated perfused livers from streptozotocin-diabetic rats.

Authors:  E M Berry; E Ziv; H Bar-On
Journal:  Diabetologia       Date:  1981-10       Impact factor: 10.122

7.  Mass spectrometric identification of aberrantly glycosylated human apolipoprotein C-III peptides in urine from Schistosoma mansoni-infected individuals.

Authors:  Crina I A Balog; Oleg A Mayboroda; Manfred Wuhrer; Cornelis H Hokke; André M Deelder; Paul J Hensbergen
Journal:  Mol Cell Proteomics       Date:  2010-01-13       Impact factor: 5.911

8.  An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III.

Authors:  G Holdsworth; J Stocks; P Dodson; D J Galton
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

9.  Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease.

Authors:  Juan C Ravell; Mami Matsuda-Lennikov; Samuel D Chauvin; Juan Zou; Matthew Biancalana; Sally J Deeb; Susan Price; Helen C Su; Giulia Notarangelo; Ping Jiang; Aaron Morawski; Chrysi Kanellopoulou; Kyle Binder; Ratnadeep Mukherjee; James T Anibal; Brian Sellers; Lixin Zheng; Tingyan He; Alex B George; Stefania Pittaluga; Astin Powers; David E Kleiner; Devika Kapuria; Marc Ghany; Sally Hunsberger; Jeffrey I Cohen; Gulbu Uzel; Jenna Bergerson; Lynne Wolfe; Camilo Toro; William Gahl; Les R Folio; Helen Matthews; Pam Angelus; Ivan K Chinn; Jordan S Orange; Claudia M Trujillo-Vargas; Jose Luis Franco; Julio Orrego-Arango; Sebastian Gutiérrez-Hincapié; Niraj Chandrakant Patel; Kimiyo Raymond; Turkan Patiroglu; Ekrem Unal; Musa Karakukcu; Alexandre Gr Day; Pankaj Mehta; Evan Masutani; Suk S De Ravin; Harry L Malech; Grégoire Altan-Bonnet; V Koneti Rao; Matthias Mann; Michael J Lenardo
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

10.  ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors.

Authors:  Natalie C Kegulian; Bastian Ramms; Steven Horton; Olgica Trenchevska; Dobrin Nedelkov; Mark J Graham; Richard G Lee; Jeffrey D Esko; Hussein N Yassine; Philip L S M Gordts
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-08       Impact factor: 10.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.